Kunihiro Tsuji, Kito Yosuke, Saori Miyajima, Sho Tsuyama
{"title":"唑苯妥昔单抗致晚期胃癌患者失蛋白性胃肠病1例。","authors":"Kunihiro Tsuji, Kito Yosuke, Saori Miyajima, Sho Tsuyama","doi":"10.1007/s13691-025-00764-z","DOIUrl":null,"url":null,"abstract":"<p><p>Zolbetuximab is a monoclonal antibody targeting Claudin 18.2 that has been approved for the treatment of advanced gastric cancer in Japan. Zolbetuximab has its anticancer effects through a variety of mechanisms, including antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Previous studies have identified edema and hypoalbuminemia as adverse events associated with zolbetuximab treatment although the mechanisms underlying these effects remain unclear. In this report, we present a case of zolbetuximab-inducing protein-losing gastroenteropathy in a patient with advanced gastric cancer. This case demonstrated protein leakage from the upper gastrointestinal tract, confirmed through protein leakage scintigraphy. This finding could provide the mechanisms of zolbetuximab-induced edema and hypoalbuminemia.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"269-273"},"PeriodicalIF":0.5000,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229402/pdf/","citationCount":"0","resultStr":"{\"title\":\"A case of zolbetuximab-induced protein-losing gastroenteropathy in a patient with advanced gastric cancer.\",\"authors\":\"Kunihiro Tsuji, Kito Yosuke, Saori Miyajima, Sho Tsuyama\",\"doi\":\"10.1007/s13691-025-00764-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Zolbetuximab is a monoclonal antibody targeting Claudin 18.2 that has been approved for the treatment of advanced gastric cancer in Japan. Zolbetuximab has its anticancer effects through a variety of mechanisms, including antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Previous studies have identified edema and hypoalbuminemia as adverse events associated with zolbetuximab treatment although the mechanisms underlying these effects remain unclear. In this report, we present a case of zolbetuximab-inducing protein-losing gastroenteropathy in a patient with advanced gastric cancer. This case demonstrated protein leakage from the upper gastrointestinal tract, confirmed through protein leakage scintigraphy. This finding could provide the mechanisms of zolbetuximab-induced edema and hypoalbuminemia.</p>\",\"PeriodicalId\":13703,\"journal\":{\"name\":\"International Cancer Conference Journal\",\"volume\":\"14 3\",\"pages\":\"269-273\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2025-04-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229402/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Cancer Conference Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s13691-025-00764-z\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Cancer Conference Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13691-025-00764-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
A case of zolbetuximab-induced protein-losing gastroenteropathy in a patient with advanced gastric cancer.
Zolbetuximab is a monoclonal antibody targeting Claudin 18.2 that has been approved for the treatment of advanced gastric cancer in Japan. Zolbetuximab has its anticancer effects through a variety of mechanisms, including antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Previous studies have identified edema and hypoalbuminemia as adverse events associated with zolbetuximab treatment although the mechanisms underlying these effects remain unclear. In this report, we present a case of zolbetuximab-inducing protein-losing gastroenteropathy in a patient with advanced gastric cancer. This case demonstrated protein leakage from the upper gastrointestinal tract, confirmed through protein leakage scintigraphy. This finding could provide the mechanisms of zolbetuximab-induced edema and hypoalbuminemia.
期刊介绍：
This online-only journal publishes original case reports on all types of cancer. In particular, we welcome not only case reports of educational value in the diagnosis and treatment of cancers, but also reports on molecularly analyzed cancer cases, including gene mutations, gene fusions, gene expression, and changes in copy number, regardless of their known clinical significance. Assessing the molecular analysis of a tumor usually requires a “cancer conference” in which experts from various fields discuss it. Even if the authors and their respective “cancer conference” were unable to determine the clinical significance of molecular changes at the time of submission and publication, their data may provide evidence that will help the scientific community develop precision medicine solutions in the future. We welcome case reports with reviews of the literature on similar cases, as they are more useful and valuable to readers than are reports of rare cases. International Cancer Conference Journal is the official publication of the Japan Society of Clinical Oncology (JSCO).
- Presents an online-only collection of original case reports on all types of cancer
- In particular, welcomes molecularly analyzed cancer cases
- The Official Publication of the Japan Society of Clinical Oncology (JSCO)
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
